ConductScience.org, home

Paper36769004

FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?

Psilopatis I and 12 others. Int J Mol Sci, 2023. Cited by 23 papers, by iCite.

Cite this record

ConductScience Library. FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far? Papers, record 36769004. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36769004

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?
PubMed
Journal
Int J Mol Sci
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
23
iCite
Relative citation ratio, by iCite
2.29
iCite
Revised in PubMed
2023-02-14
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Psilopatis IIasonhttps://orcid.org/0000-0001-8516-6242
2Damaskos CChristoshttps://orcid.org/0000-0002-5454-2564
3Garmpi AAnna
4Sarantis PPanagiotishttps://orcid.org/0000-0001-5848-7905
5Koustas EEvangelos
6Antoniou EAEfstathios A
7Dimitroulis DDimitrios
8Kouraklis GGregory
9Karamouzis MVMichail Vhttps://orcid.org/0000-0003-1369-8201
10Vrettou KKleio
11Marinos GGeorgios
12Kontzoglou KKonstantinos
13Garmpis NNikolaoshttps://orcid.org/0000-0001-9980-0056

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
Liver NeoplasmsMajor topic
United States
Humans
Nivolumab
United States Food and Drug Administration
Antibodies, Monoclonal

Source PubMed

Download CSV of topics

References102

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128655991The impact of hepatitis C virus and human immunodeficiency virus coinfection on survival in patients with hepatocellular carcinoma.Ann Gastroenterol2017https://conductscience.org/library/papers/28655991PubMed
234094688Alpha-fetoprotein response at different time-points is associated with efficacy of nivolumab monotherapy for unresectable hepatocellular carcinoma.Am J Cancer Res2021https://conductscience.org/library/papers/34094688PubMed
334799975Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis.Hepatol Res2022https://conductscience.org/library/papers/34799975PubMed
435884610Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma.Cancers (Basel)2022https://conductscience.org/library/papers/35884610PubMed
534414118Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study.Liver Cancer2021https://conductscience.org/library/papers/34414118PubMed
618650514Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008https://conductscience.org/library/papers/18650514PubMed
732007108Intensive care unit outcomes following orthotopic liver transplantation: single-center experience and review of the literature.G Chir2019https://conductscience.org/library/papers/32007108PubMed
832698317Monoclonal Antibodies in Cancer Therapy.Antibodies (Basel)2020https://conductscience.org/library/papers/32698317PubMed
930665869Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2019https://conductscience.org/library/papers/30665869PubMed
1031940757Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma.Cancers (Basel)2020https://conductscience.org/library/papers/31940757PubMed
1135739268Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.Nat Med2022https://conductscience.org/library/papers/35739268PubMed
1235877241
Pretreatment Modified Albumin-Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma.
Curr Oncol2022https://conductscience.org/library/papers/35877241PubMed
1334761470Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis.Hepatol Res2022https://conductscience.org/library/papers/34761470PubMed
1434114752Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.Cancer Rep (Hoboken)2022https://conductscience.org/library/papers/34114752PubMed
1534914889Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.Lancet Oncol2022https://conductscience.org/library/papers/34914889PubMed
1634902530Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.J Hepatol2022https://conductscience.org/library/papers/34902530PubMed
1736108891Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma.Int J Radiat Oncol Biol Phys2023https://conductscience.org/library/papers/36108891PubMed
1833677453Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy.Oncology2021https://conductscience.org/library/papers/33677453PubMed
1936368251Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis.Eur J Cancer2022https://conductscience.org/library/papers/36368251PubMed
2028839428From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world.World J Gastroenterol2017https://conductscience.org/library/papers/28839428PubMed

See all 102 referencesDownload CSV of references

Cited by18

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.

PMIDTitleJournalYearIn PapersSource
42491366Survival benefits of non-surgical triple therapy in hepatocellular carcinoma with inferior vena cava/right atrial tumor thrombus: A retrospective analysis from a multidisciplinary team.Oncol Lett2026https://conductscience.org/library/papers/42491366PubMed
42065059Navigating the Labyrinth of Hepatocellular Carcinoma: Leveraging AI/ML for Precision Oncology.Oncol Res2026https://conductscience.org/library/papers/42065059PubMed
41648957Cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) tumour expression in gastric carcinoma.Indian J Med Res2025https://conductscience.org/library/papers/41648957PubMed
41482353Augmenter of Liver Regeneration Enhances Hepatocellular Carcinoma Cell Growth Through COX-2-associated Signaling.Cancer Genomics Proteomics2026https://conductscience.org/library/papers/41482353PubMed
41461636Modeling hepatocellular carcinoma and its microenvironment on a chip.Cell Death Discov2025https://conductscience.org/library/papers/41461636PubMed
41108510Post-translational modifications in hepatocellular carcinoma: mechanisms and therapeutic potential.Med Oncol2025https://conductscience.org/library/papers/41108510PubMed
40741410Characterization of lactylation modification subtypes and the promoting role of CCL20 in hepatocellular carcinoma progression.Front Genet2025https://conductscience.org/library/papers/40741410PubMed
40686960Emerging Concepts in Immuno-Oncology: Insights from Natural Language Processing-Driven Co-Occurrence Analysis.ACS Omega2025https://conductscience.org/library/papers/40686960PubMed
40621467Antibody treatment of hepatocellular carcinoma: a review of current and emerging approaches.Front Immunol2025https://conductscience.org/library/papers/40621467PubMed
40071095
Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study.
Front Oncol2025https://conductscience.org/library/papers/40071095PubMed
39660127FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study.Front Immunol2024https://conductscience.org/library/papers/39660127PubMed
39412140Future investigative directions for novel therapeutic targets in head and neck cancer.Expert Rev Anticancer Ther2024https://conductscience.org/library/papers/39412140PubMed
39372389Clinical glycoproteomics: methods and diseases.MedComm (2020)2024https://conductscience.org/library/papers/39372389PubMed
39185414Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.Front Immunol2024https://conductscience.org/library/papers/39185414PubMed
38779103ULK1 Mediated Autophagy-Promoting Effects of Rutin-Loaded Chitosan Nanoparticles Contribute to the Activation of NF-κB Signaling Besides Inhibiting EMT in Hep3B Hepatoma Cells.Int J Nanomedicine2024https://conductscience.org/library/papers/38779103PubMed
38660476Synchronous Double Primary Tumors of Liver (Small Cell Neuroendocrine Carcinoma and Hepatocellular carcinoma): A Case Report.Hepat Med2024https://conductscience.org/library/papers/38660476PubMed
38069095Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma.Int J Mol Sci2023https://conductscience.org/library/papers/38069095PubMed
38003674Emerging Role of Circular RNAs in Hepatocellular Carcinoma Immunotherapy.Int J Mol Sci2023https://conductscience.org/library/papers/38003674PubMed

Download CSV of cited by

Genes9

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36769004

GET https://conductscience.org/api/papers/v1/36769004/references?page=2